Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: Inhibition of 5-fluorouracil metabolism by (E)-5-(2-bromovinyl)uracil

Drug Metabolism and Disposition

Volumn 28, Issue 4, 2000, Pages 467-474

  Kanamitsu, Shin Ichi ^a   Ito, Kiyomi ^b   Okuda, Haruhiro ^c   Ogura, Kenichiro ^c   Watabe, Tadashi ^c   Muro, Kei ^d   Sugiyama, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; SORIVUDINE;

ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; DRUG INHIBITION; DRUG METABOLISM; ENZYME INACTIVATION; HUMAN; HUMAN TISSUE; KINETICS; MODEL; NONHUMAN; PRIORITY JOURNAL;

ADULT; AGED; ANIMALS; ANTIMETABOLITES; ANTIVIRAL AGENTS; AREA UNDER CURVE; BLOOD PROTEINS; BLOTTING, WESTERN; BROMOURACIL; CHEMILUMINESCENT MEASUREMENTS; CYTOSOL; DEPRESSION, CHEMICAL; DRUG INTERACTIONS; FEMALE; FLUOROURACIL; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; PROTEIN BINDING; RATS;

ANIMALIA;

EID: 0034074418     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Anttila MI, Sotaniemi EA, Kairaluoma MI, Mokka RE and Sundquist HT (1983) Pharmacokinetics of ftorafur after intravenous and oral administration. Cancer Chemother Pharmacol 10:150-153.
2. Au JL-S, Walker JS and Rustum Y (1983) Pharmacokinetic studies of 5-fluorouracil and 5′-deoxy-5-fluorouridine in rab. J Pharmacol Exp Ther 227:174-180.
3. Benet LZ, Oie S and Sehwartz JB (1996) Design and optimization of dosage regimens: Pharmacokinetic data, in Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed., (Hardman JG and Limbird LE eds) p 1744. McGraw-Hill, New York.
4. Benvenuto JA, Lu K, Hall SW, Benjamin RS and Loo TL (1978) Disposition and metabolism of 1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) in humans. Cancer Res 38:3867-3870.
5. Desgranges C, Razaka G, Clercq ED, Herdewijn P, Balzarini J, Drouillet F and Bricaud H (1986) Effect of (E)-5-(2-Bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. Cancer Res 46:1094-1101.
6. Diasio RB and Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16:215-237.
7. Heggie GD, Sommadossi J-P, Cross DS, Huster WJ and Diasio RB (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47:2203-2206.
8. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions. Pharmacol Rev 50:387-411.
9. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond) 277:680-685.
10. Lu Z-H, Zhang R and Diasio RB (1992) Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J Biol Chem 267:17102-17109.
11. Lu Z-H, Zhang R and Diasio RB (1993) Comparison of dihydropyrimidine dehydrogenase from human, rat, pig and cow liver. Biochem Pharmacol 46:945-952.
12. Nakajima O, Ihara K, Isoda T, Matsumoto A, Komoda M, Imamura Y, Koyama Y and Kimura T (1980) Phase I and II studies on a mixture of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil (UFT). Gan to Kagaku Ryouhon 7:1558-1568.
13. Ogiwara T, Mikami H, Nakamaru M, Otsuka A and Kumahara Y (1990) Phase I clinical study of YN-72 (BV-araU, Brovavir) Yakuri to Chiryou 18:507-522.
14. Ogura K, Nishiyama T, Takubo H, Kalo A, Okuda H, Arakawa K, Fukushima M, Nagayama S, Kawaguchi Y and Watabe T (1998) Suicidal inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl)uracil derived from the antiviral, sorivudine. Cancer Lett 122:107-113.
15. Okuda H, Nishiyama T, Ogura K, Nagayama S, Ikeda K, Yamaguchi S, Nakamura Y, Kawaguchi Y and Watabe T (1997) Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metab Dispos 25:270-273.
16. Okuda H, Ogura K, Kalo A, Takubo H and Watabe T (1998) A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. J Pharmarol Exp Ther 287:791-799.
17. Periti P, Mazzci T, Mini E and Novelli A (1992) Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 23:106-131.
18. Pharmaceutical Affairs Bureau, Japanese Ministry of Health and Welfare (1994) A report on investigation of side effects of sorivudine: Deaths caused by interaction between sorivudine and 5-FU prodrugs (in Japanese).
19. Silverman RB (1988) Mechanism-based enzyme inactimation, in Chemistry and Enzymology, vols 1 and 2, pp 3-16, CRC Press, Boca Raton, FL.
20. Spector T, Harrington JA and Porter DJT (1993) 5-Ethynyluracil (776C85): Inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem Pharmacol 46:2243-2248.
21. Towbin H, Staehelin T and Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 76:4350-4354.
22. Yamaoka K, Tanigawara Y, Nakagawa T and Uno T (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobiodyn 4:879-885.
23. Yamashita S, Suda Y, Masada M, Nadai T and Sumi M (1989) 5-Fluorouracil derivatives with serum protein binding potencies. Chem Pharm Bull 37:2861-2863.
24. Yamazaki S, Hayashi M, Aoyama M and Ozawa N (1996) In vitro drug interactions using human tissues (in Japanese). Xenobio Metabol Dispos 11:S183
25. Yan J, Tyring SK, McCrary MM, Lee PC, Haworth S, Raymond R, Olsen S and Diasio RB (1997) The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster. Clin Pharmacol Ther 61:563-573.
26. Waley SG (1985) Kinetics of suicide substrates. Practical procedures for determining parameters. Biochem J 227:843-849.
27. Watabe T, Okuda H and Ogura K (1997) Lethal drug interactions of the new antiviral, sorivudine, with anticancer prodrugs of 5-fluorouracil. Yakugaku Zasshi 117:910-921.